JSR Life Sciences, LLC has appointed Mark W. Womack as the chief executive officer of two of its affiliate companies: KBI Biopharma, a global CDMO specializing in drug development and biologics manufacturing, and Selexis SA, a cell line development provider.   Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the U.S. Womack’s appointment is effective May 2, 2022. He w...